玻璃体内注射雷珠单抗与曲安奈德治疗视网膜静脉阻塞继发黄斑囊样水肿的疗效比较

发布时间：2018-11-20 12:49

【摘要】：目的比较玻璃体内注射雷珠单抗与曲安奈德治疗视网膜静脉阻塞(retinal vein occlusion,RVO)继发黄斑囊样水肿(cystoidmacular edema,CME)的疗效及安全性。方法 97例RVO继发CME患者按治疗方法分为雷珠单抗组(n=47)和曲安奈德组(n=50)。雷珠单抗组给予玻璃体内注射雷珠单抗0.5 mg(0.05 ml);曲安奈德组给予玻璃体内注射雷珠单抗4.0 mg(0.1 ml)。治疗后随访6个月,比较2组最佳矫正视力(best corrected visual acuity,BCVA)、黄斑中心凹厚度(central macular thickness,CMT)、眼压及并发症发生率。结果 2组治疗后各时间点BCVA均较治疗前显著提高(P0.05),但2组间比较差异无统计学意义(P0.05)。2组治疗后各时间点CMT均较治疗前显著降低(P0.05),但2组间比较差异无统计学意义(P0.05)。雷珠单抗组治疗后各时间点眼压与治疗前比较差异无统计学意义(P0.05);曲安奈德组治疗后各时间点眼压均较治疗前和雷珠单抗组显著提高(P0.05)。曲安奈德组和雷珠单抗组眼压升高发生率比较,差异有统计学意义(P0.05)。结论玻璃体内注射雷珠单抗治疗RVO继发CME,可有效提高BCVA、降低CMT,其效果与曲安奈德相当,且安全性更高。
[Abstract]:Objective to compare the efficacy and safety of intravitreous injection of Lei Zhu McAb and triamcinolone acetonide in the treatment of macular cystic edema (cystoidmacular edema,CME) secondary to retinal vein occlusion (retinal vein occlusion,RVO). Methods 97 patients with CME secondary to RVO were divided into two groups according to the treatment method: Lei Zhu McAb group (n = 47) and triamcinolone acetonide group (n = 50). Ml); triamcinolone acetonide group was given intravitreous injection of triamcinolone acetonide for 4. 0 mg (0. 1 ml). The best corrected visual acuity (best corrected visual acuity,BCVA), macular foveal thickness (central macular thickness,CMT), intraocular pressure (IOP) and incidence of complications were compared. Results the BCVA at each time point after treatment in both groups was significantly higher than that before treatment (P0.05), but there was no significant difference between the two groups (P0.05). The CMT at each time point after treatment in both groups was significantly lower than that before treatment (P0.05). However, there was no significant difference between the two groups (P0.05). There was no significant difference in intraocular pressure (IOP) between before and after treatment in Lei Zhu McAb group (P0.05); IOP at each time point in triamcinolone acetonide group was significantly higher than that before treatment and Lei Zhu McAb group (P0.05). The incidence of intraocular pressure elevation in triamcinolone acetonide group and rezuzumab group was significantly higher than that in triamcinolone acetonide group and rezuzumab group (P0.05). Conclusion intravitreous injection of Lei Zhu McAb in the treatment of CME, secondary to RVO can effectively increase the effect of reducing CMT, by BCVA, and is as effective as triamcinolone acetonide and is more safe than triamcinolone acetonide.
【作者单位】：汕头大学医学院附属第一医院;
【分类号】：R774.1

【相似文献】